Research collaboration to develop optimized affinity CD38 CAR-NK and DR5 TRAILv in Multiple Myeloma (MM) with Dr Tuna Mutis, Professor Immunotherapy of Haematological Malignancies, Department of Hematology at Amsterdam University Medical Center (UMC), Amsterdam, Netherlands.
Collaboration to investigate bortezomib and DR5 TRAIL variant expressing NK cells in cancer models with Dr Richard Childs, Clinical Director NHLBI at the National Institutes of Health (NIH), Bethesda, MD, USA. Dr Childs is a pioneer of cellular immunotherapy.
Research agreement with Dr Eva Szegezdi, Lecturer in Biochemistry, NUI Galway, Galway, Ireland and Head of the Blood Cancer Biobank in Ireland, to explore the optimal application of CLL-1 targeting strategies in pre-clinical models of Acute Myeloid Leukaemia (AML). Dr Szegezdi is an expert in apoptosis and the (AML) microenvironment.
Research collaboration with Dr David Finlay, Associate Professor, Immunometabolism, Biochemistry, Trinity Research at Trinity College, Dublin, Ireland to explore novel approaches to enhance NK cell metabolism. Dr Finlay is a world authority on NK cell metabolism. Studies are funded through an Enterprise Ireland, Innovation Partnership grant.
The Centre for Cell Manufacturing Ireland at NUI Galway, Ireland is one of the country’s first state-of-the-art licensed GMP facility. ONK has access to 250 m2 cleanroom facility to enable ongoing R&D in NK cell manufacturing.
Collaboration agreement with Anthony Nolan Cell & Gene Therapy Services for the consistent supply of ethically-sourced umbilical cord blood and cord-derived NK cells as a source of starting material for research activities and continued process development work. The Anthony Nolan team has significant know-how of NK cell biology and handling.
Robust partnership spanning process development and optimization of manufacturing through to scaled-up GMP manufacturing for initial clinical trials.
License from the National Institutes of Health (NIH), Bethesda, MD, USA for the rights to make and use a clinically-validated GMP grade EBV-LCL feeder cell line. This will enable robust NK cell expansion, supporting scale-up of the company’s manufacturing process to enable clinical trials.
Option license for the CCR7 homing receptor, for exploration in our ONKT101 program for relapsed/ refractory B cell malignancies.
Option license from Glycotope GmbH for humanized scFv targeting a novel tumor-specific MUC1 glycopeptide epitope, to support our ONKT103 program for solid tumors.
Option license from Cellerant Therapeutics for humanized scFv targeting CLL-1 to support our ONKT104 program for the treatment of AML.
Exclusive global license from Walter and Elizabeth Hall Institute (WEHI) to its patent for CISH knock out in NK cells for the treatment of cancer.
If you are interested in partnering with ONK Therapeutics, please contact us.